文献速递静脉血栓栓塞

多地区诉讼中下腔静脉滤器相关风向标案件的结局

Outcomes of bellwether cases related to inferior vena cava filters in multidistrict litigations.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2022-07-08

研究通过LexisNexis数据库回顾下腔静脉滤器多地区诉讼中的风向标案件,共识别678例相关案件,其中12例为风向标案件。陪审团审判中2例(16.7%)初判原告胜诉,其中1例后被法官撤销;其余10例(83.3%)由法官和陪审团判制造商胜诉。所有法官审判均判制造商胜诉,提示法官认为患者所诉并发症属于下腔静脉滤器使用的预期风险范围。

要点

  • 12例风向标案件中,10例(83.3%)判制造商胜诉,2例(16.7%)初判原告胜诉。
  • 所有法官审判均判制造商胜诉,法官认为并发症属预期风险范围。
  • 作者强调治疗医生有法律责任充分告知下腔静脉滤器的相关风险。

核心结论

  • 所有法官审判的裁决均支持制造商,提示法官认为患者所诉并发症属于下腔静脉滤器使用的预期风险范围。
  • 研究强调治疗医生有法律责任充分告知患者下腔静脉滤器的所有相关风险。
  • 研究提示在针对制造商的产品责任案件中,医生仍可能被认定负有责任。
  • 作者建议医生应继续积极监测患者以优化下腔静脉滤器取出窗口。

研究设计与样本

  • 使用法律研究数据库LexisNexis识别所有与下腔静脉滤器相关的案件,排除与多地区诉讼无关的案件。
  • 从LexisNexis子公司Law360获取进入陪审团审判的风向标案件的法庭程序文件。
  • 回顾原告、滤器型号、报告的并发症、提出的索赔、决策机构、裁决和赔偿等数据。

主要发现

  • 数据库中共发现678例与下腔静脉滤器相关的案件,其中12例被确定为多地区诉讼的风向标案件。
  • 12例中2例(16.7%)在陪审团审判中初判原告胜诉,其中1例的判决后来被法官撤销。
  • 其余10例(83.3%)由法官和陪审团判制造商胜诉。

临床怎么用

  • 治疗医生有法律责任充分告知患者下腔静脉滤器的所有相关风险。
  • 在针对制造商的产品责任案件中,医生仍可能被认定负有责任。
  • 作者建议医生应继续积极监测患者以优化下腔静脉滤器取出窗口。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In the present study, we identified and reviewed the outcomes of bellwether cases related to inferior vena cava (IVC) filter multidistrict litigations (MDLs). METHODS: The legal research database, LexisNexis (New York, NY), was used to identify all cases related to IVC filters. Cases unrelated to the MDLs were excluded. Court documents recording the proceedings for bellwether cases sent to jury trials were retrieved from the LexisNexis subsidiary, Law360. Data on plaintiffs, filter models, reported complications, filed claims, decision-making body, verdicts, and rewards were reviewed. RESULTS: A total of 678 cases pertaining to IVC filters were found in the database, of which 12 were identified as bellwether cases for MDL. Of the 12, 2 (16.7%) were initially ruled in favor of the plaintiffs in jury trials, although the judgment for 1 of these was later vacated by a judge. The remaining 10 (83.3%) had been decided in favor of the manufacturers by judges and juries. CONCLUSIONS: Verdicts in all bench trials were in favor of manufacturers, suggesting that judges perceived the presented complications by patients to be within the normal realm of the expected risk of IVC filter use. The findings from the present study have emphasized the treating physicians' legal responsibility to adequately warn patients of all the associated risks with IVC filters. The findings have also indicated that physicians can still be found liable in product liability cases directed at manufacturers. Physicians should continue to actively monitor patients to optimize the IVC retrieval windows.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Ahmad Y, Wadhwa V, Funaki B, et al. Outcomes of bellwether cases related to inferior vena cava filters in multidistrict litigations. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35810992. doi:10.1016/j.jvsv.2022.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。